Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2019 | Checkpoint inhibition in mesothelioma: the CONFIRM trial

Dean Fennell • 24 Jan 2019
BTOG 2019
Mesothelioma Checkpoint Inhibitors Nivolumab
CONFIRM

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, gives an overview of the CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM; NCT03063450) trial, which is investigating nivolumab. This video was recorded at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

More from Dean Fennell

1:14
ATOMIC: treating mesothelioma with an arginine-degrading enzyme and combination chemotherapy
Dean Fennell • 27 Apr 2023
3:34
Role of immunotherapy in the management of mesothelioma
Dean Fennell • 31 Mar 2023
6:43
Personalized medicine in mesothelioma
Dean Fennell • 31 Mar 2023
1:54
Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma
Dean Fennell • 21 May 2021

Related Videos

1:44
Overview and advances in tumor treatment fields (TTFields)
Ticiana Leal • 27 Feb 2024
2:51
Bringing change with TTFields therapy in ovarian cancer
Jalid Sehouli • 21 Oct 2023
1:42
Highlights in ADCs from WCLC 2023
Amin Nassar • 18 Sep 2023
2:28
A morphomolecular classification of malignant pleural mesothelioma
Lynnette Fernandez-Cuesta • 4 Jun 2023
The content of VJOncology is intended for healthcare professionals